![The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2013/05/web-cover-classics-with-logo-medicine-BW-small-jpg-350x250.jpg){kind=logo}
Immune-related response criteria captures tumor response to therapy [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
Tag: ipilimumab
#VisualAbstract: Time-of-infusion with immunotherapy may impact survival outcomes for patients with advanced melanoma
Click to read this study in Lancet Oncology.
Nivolumab combination therapies improved overall survival in patients with advanced esophageal squamous cell carcinoma
1. Nivolumab in combination with chemotherapy or ipilimumab significantly prolonged overall survival compared to chemotherapy alone. 2. Common treatment-related adverse ...
#VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males
Click to read this study in JAMA Network Open.
#VisualAbstract: Greater immunosuppression is associated with worse outcomes in patients with advanced melanoma receiving ipilimumab and anti-PD-1 therapy
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Ipilimumab plus anti-PD-1 therapy is effective in patients with anti-PD-L1 resistant metastatic melanoma
Click to read the study in The Lancet Oncology.
#VisualAbstract: Liver metastases and LDH levels may be superior prognostic biomarkers for patients with metastatic melanoma
Click to read the study in JAMA Oncology.
#VisualAbstract: Combined anti-PD-1 and anti-CTLA-4 blockade improves survival among patients with BRAF-mutated melanoma and elevated LDH
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Nivolumab plus ipilimumab is safe and effective for the treatment of advanced melanoma (CheckMate 218)
Click to read the study in Melanoma Research.